![]() Regence BlueShield (WA State) – Regence Guidelines BCBS Colorado Guidelinesġ999 Academy of Managed Care Pharmacy (AMCP) Committee organized to draft standard unsolicited request for evidence to support formulary deliberations 2000 – AMCP Format Version 1.0 AMCP Board of Directors approves AMCP Format as a generalized unsolicited request AMCP Board mandates evaluation of the AMCP Format 2002 – AMCP Format Version 2.0 2005 – AMCP Format Version 2.1 2005 – WellPoint Health Technology Assessment Guidelines Version 5.1 2009 – AMCP Format Version 3.0 2012– AMCP Format Version 3.1 RESPONSE Regional efforts to improve access to better and more complete evidence by specifying information needs. But, this information was not included in product labels despite systematic attempts (FDMA SEC 114, etc.) DDMAC regulates content of information from manufacturer to health care professionals and health plans – Relatively little data beyond what is included in the label. PROBLEM Growing recognition that information (Formulary Kits) on new products provided by PhRMA to health plans and other payers was promotional and insufficient to inform evidence-based decision-making Rise of HEOR units within PhRMA to generate evidence of product value. In this environment, a robust market access launch plan developed as early as possible (launch minus 24 months) is critical to prepare the market for appropriate formulary access, maximize brand sales trajectory, and contribute to the long-term financial success of the brand.Ī well-defined market access launch plan personalized to brand access requirements that outlines key action items, timing, and ownership by function is a critical component to ensure achievement of launch objectives.Īventria’s LEAP model enables you to establish interdependencies across stakeholder functions and ensure transparency and accountability to deliver launch excellence execution, as well as ensure a continuous improvement approach to successfully support future launches.Presentation Developed for the Academy of Managed Care Pharmacy February 2015 In addition, organized provider groups (health systems, IDNs, community practices) are exerting similar cost scrutiny characterized by greater reliance on evidence-based medicine and value-based care. Drug innovation and advancements in therapy are providing patients with new treatment options however, challenges stem from the growth and impact on the cost of care.Īs a result, payers are exercising increased scrutiny through utilization management, narrowing formularies, stricter prior authorizations, formulary exclusions, and requests for greater price concessions. The marketplace is evolving at a rapid rate.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |